File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1002/hed.20093
- Scopus: eid_2-s2.0-10044284179
- PMID: 15390194
- WOS: WOS:000225422100003
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma
Title | Effectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma |
---|---|
Authors | |
Keywords | Adolescent Adult Aged Aged, 80 and over Brachytherapy/*methods Carcinoma/mortality/pathology/radiotherapy Cohort Studies Combined Modality Therapy Dose Fractionation Dose-Response Relationship, Radiation Female Follow-Up Studies Humans Immunohistochemistry Male Middle Aged Nasopharyngeal Neoplasms/mortality/pathology/*radiotherapy Neoplasm Recurrence, Local/mortality/pathology/*radiotherapy/*surgery Neoplasm Staging Radiosurgery/*methods Radiotherapy Dosage Retrospective Studies Risk Assessment *Salvage Therapy Survival Analysis Treatment Outcome |
Issue Date | 2004 |
Citation | Head Neck, 2004, v. 26 n. 12, p. 1024-1030 How to Cite? |
Abstract | BACKGROUND: Nasopharyngeal carcinoma (NPC) with local persistence after primary radiotherapy carries a high risk of treatment failure. We compared the effectiveness of brachytherapy and a fractionated stereotactic radiotherapy (SRT) boost in improving tumor control. METHODS: We retrospectively reviewed the records of 755 patients with NPC treated from 1994 to 2001. Fifty-two patients (7%) had persistent local disease, but seven of them were unsuitable for radiotherapy boost. Overall, 24 patients received brachytherapy boost at a median dose of 20 Gy, and 21 patients received an SRT boost at a median dose of 15 Gy. RESULTS: Despite the radiotherapy boost, the overall 3-year local failure-free control rate was still significantly lower for patients with persistent disease than for the rest (71% vs 86%, p < .01). Only the SRT subgroup achieved a local failure-free control rate close to that of the complete responders (82% vs 86%, p = .71). CONCLUSIONS: SRT boost is more effective in reverting the poor prognostic influence of local persistent disease. |
Persistent Identifier | http://hdl.handle.net/10722/220035 |
ISSN | 2023 Impact Factor: 2.3 2023 SCImago Journal Rankings: 1.034 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yau, TK | - |
dc.contributor.author | Sze, WM | - |
dc.contributor.author | Lee, WMA | - |
dc.contributor.author | Yeung, MW | - |
dc.contributor.author | Leung, KC | - |
dc.contributor.author | Hung, WM | - |
dc.contributor.author | Chan, WI | - |
dc.date.accessioned | 2015-10-16T06:16:35Z | - |
dc.date.available | 2015-10-16T06:16:35Z | - |
dc.date.issued | 2004 | - |
dc.identifier.citation | Head Neck, 2004, v. 26 n. 12, p. 1024-1030 | - |
dc.identifier.issn | 1043-3074 | - |
dc.identifier.uri | http://hdl.handle.net/10722/220035 | - |
dc.description.abstract | BACKGROUND: Nasopharyngeal carcinoma (NPC) with local persistence after primary radiotherapy carries a high risk of treatment failure. We compared the effectiveness of brachytherapy and a fractionated stereotactic radiotherapy (SRT) boost in improving tumor control. METHODS: We retrospectively reviewed the records of 755 patients with NPC treated from 1994 to 2001. Fifty-two patients (7%) had persistent local disease, but seven of them were unsuitable for radiotherapy boost. Overall, 24 patients received brachytherapy boost at a median dose of 20 Gy, and 21 patients received an SRT boost at a median dose of 15 Gy. RESULTS: Despite the radiotherapy boost, the overall 3-year local failure-free control rate was still significantly lower for patients with persistent disease than for the rest (71% vs 86%, p < .01). Only the SRT subgroup achieved a local failure-free control rate close to that of the complete responders (82% vs 86%, p = .71). CONCLUSIONS: SRT boost is more effective in reverting the poor prognostic influence of local persistent disease. | - |
dc.language | eng | - |
dc.relation.ispartof | Head Neck | - |
dc.subject | Adolescent | - |
dc.subject | Adult | - |
dc.subject | Aged | - |
dc.subject | Aged, 80 and over | - |
dc.subject | Brachytherapy/*methods | - |
dc.subject | Carcinoma/mortality/pathology/radiotherapy | - |
dc.subject | Cohort Studies | - |
dc.subject | Combined Modality Therapy | - |
dc.subject | Dose Fractionation | - |
dc.subject | Dose-Response Relationship, Radiation | - |
dc.subject | Female | - |
dc.subject | Follow-Up Studies | - |
dc.subject | Humans | - |
dc.subject | Immunohistochemistry | - |
dc.subject | Male | - |
dc.subject | Middle Aged | - |
dc.subject | Nasopharyngeal Neoplasms/mortality/pathology/*radiotherapy | - |
dc.subject | Neoplasm Recurrence, Local/mortality/pathology/*radiotherapy/*surgery | - |
dc.subject | Neoplasm Staging | - |
dc.subject | Radiosurgery/*methods | - |
dc.subject | Radiotherapy Dosage | - |
dc.subject | Retrospective Studies | - |
dc.subject | Risk Assessment | - |
dc.subject | *Salvage Therapy | - |
dc.subject | Survival Analysis | - |
dc.subject | Treatment Outcome | - |
dc.title | Effectiveness of brachytherapy and fractionated stereotactic radiotherapy boost for persistent nasopharyngeal carcinoma | - |
dc.type | Article | - |
dc.identifier.email | Lee, WMA: awmlee@hkucc.hku.hk | - |
dc.identifier.authority | Lee, WMA=rp02056 | - |
dc.identifier.doi | 10.1002/hed.20093 | - |
dc.identifier.pmid | 15390194 | - |
dc.identifier.scopus | eid_2-s2.0-10044284179 | - |
dc.identifier.hkuros | 266069 | - |
dc.identifier.volume | 26 | - |
dc.identifier.issue | 12 | - |
dc.identifier.spage | 1024 | - |
dc.identifier.epage | 1030 | - |
dc.identifier.isi | WOS:000225422100003 | - |
dc.identifier.issnl | 1043-3074 | - |